This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-16 and is reviewed periodically as new material appears.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
The non-protein amino acid-accumulating clade, also known as the Canavanine-accumulating clade, is a clade of the flowering plant subfamily Faboideae (or Papilionoideae) that includes the majority of agriculturally-cultivated legumes. It is characterized by the accumulation of the non-proteinogenic amino acid canavanine in the seeds—a deterrent against herbivory. This phylogenetic trait was first recognized in the early 1980s. This clade is consistently resolved in molecular phylogenies. It contains many economically important genera, including Cicer, Glycine, Medicago, Phaseolus, Trifolium, Vicia, and Vigna.
With no potassium intake, it is excreted at about 200 mg per day until, in about a week, potassium in the serum declines to a mildly deficient level of 3.0–3.5 mmol/L. If potassium is still withheld, the concentration continues to fall until a severe deficiency causes eventual death. The potassium moves passively through pores in the cell membrane. When ions move through ion transporters (pumps) there is a gate in the pumps on both sides of the cell membrane and only one gate can be open at once. As a result, approximately 100 ions are forced through per second. Ion channels have only one gate, and there only one kind of ion can stream through, at 10 million to 100 million ions per second. Calcium is required to open the pores, although calcium may work in reverse by blocking at least one of the pores. Carbonyl groups inside the pore on the amino acids mimic the water hydration that takes place in water solution by the nature of the electrostatic charges on four carbonyl groups inside the pore.
we agree with the Commissioner that there is strong circumstantial evidence that the Oil for Food Programme was used by the Iraqi government, with Mr Galloway's connivance, to fund the campaigning activities of the Mariam Appeal. It found that Galloway's use of parliamentary resources to support his work on the Mariam Appeal "went beyond what was reasonable" and "we recommend that he apologise to the House, and be suspended from its service for a period of 18 actual sitting days." Galloway's suspension was not intended to be immediate, and he was given the opportunity to defend himself in front of the committee members in the House of Commons on 23 July 2007. During the debate, Galloway repeatedly called into question the motives of the members of the Select Committee, in particular alleging that some of them were members of a political organisation named "Indict" and were persecuting him for speaking out against the Iraq War. Speaker Michael Martin warned Galloway that his accusations were not relevant to the matter at hand, but he rejected the warning and responded by saying that Martin would have to order him out of the house if he had any issue with the accusations. Martin therefore named Galloway, leading to the attending members voting to trigger his suspension from parliament that day rather than wait until after the summer recess as had been recommended. The Respect Party split in the autumn of 2007, with the Socialist Workers' Party and Galloway's wing of Respect blaming each other for what he described as a "car crash on the left".
The daily intake of HMF may underlie high variations due to individual consumption-patterns. It has been estimated that the intakes range between 4 mg - 30 mg per person per day, while an intake of up to 350 mg can result from, e.g., beverages made from dried plums.
allele One of multiple alternative versions of an individual gene, each of which is a viable DNA sequence occupying a given position, or locus, on a chromosome. For example, in humans, one allele of the eye-color gene produces blue eyes and another allele of the same gene produces brown eyes.
Sources: en.wikipedia.org
Knoxville's Greek community is perhaps best known for its restaurateurs, namely the Regas family, who operated a restaurant on North Gay Street from 1919 to 2010, and the Paskalis family, who founded the Gold Sun Cafe on Market Square around 1909. Notable members of Knoxville's Jewish community included jeweler Max Friedman and department store owner Max Arnstein. One of Knoxville's largest migrant groups consisted of rural people who moved to the city from the surrounding rural counties, often seeking wage-paying jobs in mills. Many of Knoxville's political and business leaders throughout the 20th century hailed from rural areas of Southern Appalachia.
=== Surgical debridement === Surgical or "sharp" debridement and laser debridement under anesthesia are the fastest methods of debridement. They are very selective, meaning that the person performing the debridement has nearly complete control over which tissue is removed and which is left behind. Surgical debridement can be performed in the operating room or bedside, depending on the extent of the necrotic material and a patient's ability to tolerate the procedure. The surgeon will typically debride tissue back to viability, as determined by tissue appearance and the presence of blood flow in healthy tissue.
If the branched and complex structures seen in cpDNA experiments are real and not artifacts of concatenated circular DNA or broken circles, then a D-loop mechanism of replication is insufficient to explain how those structures would replicate. At the same time, homologous recombination does not expand the multiple A --> G gradients seen in plastomes. Because of the failure to explain the deamination gradient as well as the numerous plant species that have been shown to have circular cpDNA, the predominant theory continues to hold that most cpDNA is circular and most likely replicates via a D loop mechanism.
This medication will be given intravenously for your heart disease. You will have continuously ECG monitoring during the infusion and 4 hours after your infusion. Some of the minor side effects are headache and irregular heartbeat. If you experience chest pain and respiratory difficulties, you should report to your doctors immediately.
Sources: en.wikipedia.org
The identification of suitable matrix compounds is determined to some extent by trial and error, but they are based on some specific molecular design considerations. They are of a fairly low molecular weight (to allow easy vaporization), but are large enough (with a low enough vapor pressure) not to evaporate during sample preparation or while standing in the mass spectrometer. They are often acidic, therefore act as a proton source to encourage ionization of the analyte. Basic matrices have also been reported. They have a strong optical absorption in either the UV or IR range, so that they rapidly and efficiently absorb the laser irradiation. This efficiency is commonly associated with chemical structures incorporating several conjugated double bonds, as seen in the structure of cinnamic acid. They are functionalized with polar groups, allowing their use in aqueous solutions. They typically contain a chromophore. The matrix solution is mixed with the analyte (e.g. protein-sample). A mixture of water and organic solvent allows both hydrophobic and water-soluble (hydrophilic) molecules to dissolve into the solution. This solution is spotted onto a MALDI plate (usually a metal plate designed for this purpose). The solvents vaporize, leaving only the recrystallized matrix, but now with analyte molecules embedded into MALDI crystals. The matrix and the analyte are said to be co-crystallized. Co-crystallization is a key issue in selecting a proper matrix to obtain a good quality mass spectrum of the analyte of interest.
== Mechanism of action == The perceived sweetness of aspartame (and other sweet substances like acesulfame potassium) in humans is due to its binding of the heterodimer G protein-coupled receptor formed by the proteins TAS1R2 and TAS1R3. Rodents do not experience aspartame as sweet-tasting, due to differences in their taste receptors.
==== Metal ions ==== Several metal cations have high affinities for imidazole, the functional group of the His-tag. Divalent cation M2+ (M = Mn, Fe, Co, Ni, Cu, Zn etc) transition metal imidazole complexes are most frequently used for this purpose. The choice of cation is generally a compromise between binding capacity and purity. Nickel is often used as it offers a good balance between these factors, while cobalt can be used when it is desired to increase the purity of purification as it has less affinity for endogenous proteins; binding capacity however is lower compared with nickel.
"It seems to me", Mellanby wrote to Florey, "that the line of work you are suggesting will be interesting and may prove to be of practical importance." Florey felt that far more would be required. On 1 November 1939, Henry M. "Dusty" Miller Jr from the Natural Sciences Division of the Rockefeller Foundation paid Florey a visit. Miller encouraged Florey to apply for funding from the foundation and supported his application. "The work proposed", Florey wrote in the application letter, "in addition to its theoretical importance, may have practical value for therapeutic purposes." His application was approved, with the foundation allocating US$5,000 (£1,250) per annum for five years. The Oxford team's first task was to obtain a sample of penicillin mould. This turned out to be easy. Georges Dreyer, Florey's predecessor, had obtained a sample of the mould in 1930 for his work on bacteriophages, viruses that infect bacteria. Dreyer had lost interest in penicillin when he discovered that it was not a bacteriophage, but he had continued to cultivate it. Dreyer had died in 1934, but Campbell-Renton had continued to culture the mould and was able to supply it to the Oxford team. The next task was to grow sufficient mould to extract enough penicillin for laboratory experiments. The mould was cultured on a surface of liquid Czapek-Dox medium. Over the course of a few days it formed a yellow gelatinous skin covered in green spores. Beneath this, the liquid became yellow and contained penicillin. The team determined that the maximum yield was achieved in ten to twenty days.
Petrov underwent intense questioning by his superiors about his actions. Initially, he was praised for his decision. General Yuri Votintsev, then commander of the Soviet Air Defense's Missile Defense Units, who was the first to hear Petrov's report of the incident (and the first to reveal it to the public in 1998), stated that Petrov's "correct actions" were "duly noted". Petrov himself stated he was initially praised by Votintsev and was promised a reward, but recalled that he was also reprimanded for improper filing of paperwork with the pretext that he had not described the incident in the military diary. He received no reward. According to Petrov, this was because the incident and other bugs found in the missile detection system embarrassed his superiors and the influential scientists who were responsible for it, so that if he had been officially rewarded, they would have had to be punished. He was reassigned to a less sensitive post, took early retirement (although he emphasized that he was not "forced out" of the army, as is sometimes claimed by Western sources), and suffered a nervous breakdown. Oleg Kalugin, a former KGB chief of foreign counter-intelligence who knew Soviet leader Yuri Andropov well, said that Andropov's distrust of American leaders was profound. It was conceivable that if Petrov had declared the satellite warnings valid, such an erroneous report could have provoked the Soviet leadership into becoming bellicose. Kalugin said: "The danger was in the Soviet leadership thinking, 'The Americans may attack, so we better attack first.'"
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.